417 related articles for article (PubMed ID: 24342209)
21. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
23. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
[TBL] [Abstract][Full Text] [Related]
25. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
26. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
[TBL] [Abstract][Full Text] [Related]
27. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
28. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
29. Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease.
Ha KS; Lee J; Jang GY; Lee J; Lee KC; Son CS; Lee JW
Am J Cardiol; 2015 Jul; 116(2):301-6. PubMed ID: 25975725
[TBL] [Abstract][Full Text] [Related]
30. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
[TBL] [Abstract][Full Text] [Related]
31. Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease - A Multicenter Retrospective Study.
Okuma Y; Suda K; Nakaoka H; Katsube Y; Mitani Y; Yoshikane Y; Ichida F; Matsushita T; Shichino H; Shiraishi I; Abe J; Hiroe M; Yoshida T; Imanaka-Yoshida K
Circ J; 2016 Oct; 80(11):2376-2381. PubMed ID: 27746411
[TBL] [Abstract][Full Text] [Related]
32. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[TBL] [Abstract][Full Text] [Related]
34. [Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment].
Fu SF; Yu DL; Lv DY; Chen FY
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Jan; 16(1):44-7. PubMed ID: 24461177
[TBL] [Abstract][Full Text] [Related]
35. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
Liu J; Ye B; Su D; Qin S; Zhao W; Pang Y
Clin Rheumatol; 2023 Jan; 42(1):167-177. PubMed ID: 36129563
[TBL] [Abstract][Full Text] [Related]
37. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[TBL] [Abstract][Full Text] [Related]
38. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
Tsai MH; Huang YC; Yen MH; Li CC; Chiu CH; Lin PY; Lin TY; Chang LY
J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595
[TBL] [Abstract][Full Text] [Related]
39. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Huang CF; Wang L; Hwang KP; Yang KD
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[TBL] [Abstract][Full Text] [Related]
40. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
